IDIOPATHIC PULMONARY FIBROSIS: A NEW ERA
Saturday, October 10, 2015
School of Nursing Auditorium
School of Nursing
University of Kansas Medical Center
Kansas City, Kansas
Sponsored by the Pulmonary Disease Department and University of Kansas Medical Center
Continuing Education & Professional Development
COURSE DIRECTOR:
Mark Hamblin, MD, FCCP, Assistant Professor, University of Kansas Pulmonary Critical Care
Division. Dr. Hamblin is Director of The KU Interstitial Lung Disease Center, which is one of 21 of the
Pulmonary Fibrosis Foundation's National Care Network Centers, as well as The Director for The
Rare Lung Disease Clinic that is part of the International Rare Lung Disease Consortium. Dr.
Hamblin's research has focused on Idiopathic Pulmonary Fibrosis and educating residents on the
detection and progression of this disease.
OVERVIEW:
There will be 5 speakers presenting at the conference. All are specialists in pulmonary fibrosis at
either the University of Kansas Medical Center or Washington University, which are both designated
Pulmonary Fibrosis Foundation Centers of Excellence. The speakers will develop the content based
on evidence from the existing pulmonary fibrosis literature. The content will be reviewed by the
directors of the pulmonary fibrosis centers prior to presentation to ensure the evidence based nature
of the content.
The course content will be built around a strategy to highlight our evolution of the understanding of
pulmonary fibrosis. The initial lecture will focus on our current understanding of the natural history
of pulmonary fibrosis in terms of symptom onset, progression, and change over time. It will
highlight existing knowledge of environmental and genetic factors that play a role in disease
development. It will also discuss co-morbid conditions that contribute to progression of the disease.
It will conclude with an initial presentation of therapeutic options. The second lecture will provide a
more in depth look at drug therapy focusing on nuances of the medications that might influence
treatment decisions for an individual patient. The third lecture will focus on diagnostic nuances that
could lead to an incorrect diagnosis and treatment algorithm. This lecture will highlight pitfalls in
imaging acquisition, deficiencies in the lab evaluation, as well as the rational use of lung biopsy in the
diagnostic process. The final didactic lecture will focus on autoimmune variants of the disease with a
focus this year on the anti-synthetase syndrome, which is an often under-recognized phenomenon.
The afternoon session will encompass small group discussion of various case presentations that
exemplify real world challenges in the diagnosis and treatment of pulmonary fibrosis. Specific
educational points that will be highlighted includes optimal work-up for chronic cough, the role of
HRCT, and the importance of appropriate techniques to elicit diagnostic information that could
impact treatment decisions. There will be a focus on drug therapy and management of adverse
effects. Attendees will also be encouraged to submit their own challenging cases for review and
discussion.
There will be a concurrent afternoon session that will focus on patients and care givers. This will
include lectures in a more informal interactive format that will focus on the natural history of the
disease, and co-morbid conditions. There will also be a discussion of oxygen, and options for
patients. It will conclude with a discussion of current and future therapeutic options.
TARGET AUDIENCE:
This symposium is designed for pulmonologists, lung radiologists, internal medicine and family
physicians as well as nurse practitioners, nurses and other health professionals.
OBJECTIVES:
At the completion of this symposium participants should be able to:
1. Know how to order an HRCT for the most complete diagnostic information.
2. Describe the criteria for HRCT classification of definite, possible, inconsistent UIP patterns.
3. Explain the disease states that could be encompassed by the inconsistent UIP pattern and
differences in treatment strategy.
4. List the indications for drug therapy for IPF.
5. Examine the contraindications to individual therapies for individual patients.
6. Cite the important co-morbid conditions that should be addressed in the work-up of IPF.
7. Describe the diagnostic work-up for the Anti-synthetase syndrome.
8. Identify key lab abnormalities that will affect treatment decisions for the Anti-synthetase
syndrome.
9. Discuss the nuances of lung pathology in UIP that might suggest an alternative diagnostic etiology
than IPF.
PLANNING COMMITTEE:
Mark Hamblin, MD, FCCP, Assistant Professor, Pulmonary Disease, University of Kansas Medical
Center, Kansas City, Kan.
Kristin Simpson, RN, BSN, University of Kansas Medical Center, Kansas City, Kan.
Marla Sutton, MS, Senior Program Manager, Office of Continuing Education and Professional
Development , University of KS Medical Center, Kansas City, Kan.
Terri Schmitz, BSN, RN, Senior Coordinator, University of Kansas Medical Center Area
Health Education Center, University of KS Medical Center, Kansas City, Kan.
ACCREDITATION:
All participants are required to sign attendance rosters at the beginning of each day. A certificate
of completion will be provided to all activity participants based on completion of the program
evaluation, documentation of actual attendance time, meeting minimum attendance requirements
specific to the activity, and payment in full. If you are not paid in full, a link to complete evaluation and
get your certificate will be emailed to you upon receipt of payment.
Physicians: The University of Kansas Medical Center Office of Continuing Medical Education
& Professional Development is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
The KU Medical Center Office of Continuing Medical Education designates this live activity
for a maximum of 8 AMA PRA Category 1 Credits TM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses: Up to 8 contact hours will be awarded to all individuals based on documentation of
actual attendance time, meeting minimum attendance requirements specific to the activity, and
payment in full.
ACKNOWLEDGEMENTS:
This symposium is supported in part by an educational grant from Boehringer -Ingelheim.
EXHIBITS:
Commercial vendors are invited to exhibit at this meeting. Limited exhibit space will be available.
Call Suzy Williams at 913-588-4488 or e-mail swilliams16@kumc.edu for an application or more
information.
FACULTY:
Mark Hamblin, MD, FCCP University of Kansas Medical Center, Kansas City, KS
Lucas Pitts, MD, FCCP; University of Kansas Medical Center, Kansas City, KS
Tonya Russell, MD, FCCP; Barnes-Jewish Hospital/Washington University, St. Louis, MO
Adrian Shifren, MD, FCCP; Barnes-Jewish Hospital/Washington, St. Louis, MO
Mark L Wencel, MD, FCCP; Via Christi Clinic, University of Kansas Medical Center-Wichita,
Wichita, KS
AGENDA:
Session I
8:00 a.m. Welcome & Introduction
Mark Hamblin, MD, FCCP; University of Kansas Medical Center University
8:15 a.m. Overview of Idiopathic Pulmonary Fibrosis
Tonya Russell, MD, FCCP; Barnes-Jewish Hospital/Washington University
9:15 a.m. Diagnostic Nuances – Imaging, Pathology, and Treatment
Mark Hamblin, MD, FCCP; University of Kansas Medical Center
10:15 a.m. Break
10:30 a.m. Esbriet, OFEV, and the Future of Pulmonary Fibrosis Therapy
Adrian Shifren, MD, FCCP; Barnes-Jewish Hospital/Washington
11:30 a.m. Autoimmune-ILD: Focus on the Anti-Synthetase Syndrome
Lucas Pitts, MD, FCCP; University of Kansas Medical Center
12:30 p.m. Break for Lunch
Session II Clinical Case Reviews/Multidisciplinary Group Case Review
1:15 p.m. Clinical Case Review
4:00 p.m. Expert Panel Question and Answer
4:30 p.m. Adjourn
Session III Patient and Care-Giver Session
1:15 p.m. Understanding Pulmonary Fibrosis - Diagnostic Nuances and the Impact on Treatment and
Survival
Mark L Wencel, MD, FCCP; Via Christi Clinic, University of Kansas Medical Center-Wichita
2:15 p.m. Understanding Your Oxygen Rights
Mark Hamblin, MD, FCCP; University of Kansas Medical Center
3:15 p.m. Esbriet, OFEV, and the Future of Pulmonary Fibrosis Therapy
Adrian Shifren, MD, FCCP; Barnes-Jewish Hospital/Washington
4:15 p.m. Expert Panel Question and Answer
4:30 p.m. Adjourn
REGISTRATION AND FEES:
Payment is required at the time of registration. Only registrations accompanied with payment will be
accepted. Please register in advance. Fees include course materials, continental breakfast, lunch,
refreshments and continuing education credit.
Physician $50.00
KU Physician $40.00
Nurse $40.00
KU Nurse $30.00
Other Health Professional $25.00
PRIVACY POLICY:
KU Continuing Education does not share, sell, or rent its mailing lists. You have our assurance that
any information you provide will be held in confidence by KU Continuing Education.
We occasionally use mailing lists that we have leased. If you receive unwanted communication from
KUCE, it is because your name appears on a list we have acquired from another source. In this case,
please accept our apologies.
NONDISCRIMINATION POLICY:
The University of Kansas Medical Center prohibits discrimination on the basis of race, color,
ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation,
marital status, parental status, gender identity, gender expression and genetic information in the
University's programs and activities. The following person has be designated to handle inquiries
regarding the non-discrimination polices: Natalie Holick, Director, Equal Opportunity Office,
NHolick@kumc.edu, Mail Stop 2014, 4330 Shawnee Mission Parkway, Fairway, KS 66205, 913-5888011, 711TTY
PROGRAM ACCESSIBILITY:
We accommodate persons with disabilities. Please call 785-864-5823 and a KU Medical Center
Continuing Education & Professional Development representative will contact you to discuss your
needs. To ensure accommodation, please register at least two weeks before the start of the course. See
the nondiscrimination policy above.
The University of Kansas Medical Center is an AA/EO Title IX institution.